drugset / Trial / NCT00069940

Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor

NCT00069940

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may cause a stronger immune response and kill more tumor cells. PURPOSE: This phase I trial is studying the side effects of vaccine therapy when given together with sargramostim in treating patients with advanced sarcoma or brain tumor.

Timeline

Start
2000-12
Primary completion
2006-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Subject telomerase: 540-548 peptide vaccine Vaccine Subcutaneous
Background sargramostim Protein / enzyme biologic Subcutaneous